A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF KALMEGHANAVAYASA LAUHA AND AROGYAVARDHINI VATI IN YAKRIT ROGA WITH SPECIAL REFERENCE TO MAFLD
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a major worldwide health issue, prompting a shift in the perception and classification of nonalcoholic fatty liver disease (NAFLD )
In Ayurveda, it is believed that mandagni is the root cause of all udararogas. There are 8 types of udararoga have been described in samhitas .Metabolic associated fatty liver disease has increased rapidly due to our faulty lifestyle and dietary habits like excessive use of fats, antagonistic food combinations etc. it is increasing parallel with obesity, diabetes mellitus and metabolic syndrome. The treatment presently available are not satisfactory that can restrict hepatic steatosis and to limit liver cell injury and the occurrence of inflammation and fibrosis. Currently it is a great challenge for us to develop a drug that is effective in MAFLD. Also Increased demand in Ayurveda treatment, as ayurveda has become the safe place due to its non or negligible side effect, cost effectiveness of the drugs and easy availability of medicines.
Therefore, this study was planned to assess the role of Kalmeghnavayasa Lauha and Arogyavardhini vati with special reference to Metabolic associated fatty liver disease [MAFLD]. The study entitled as "A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF KALMEGHANAVAYASA LAUHA AND AROGYAVARDHINI VATI IN YAKRIT ROGA WITH SPECIAL REFERENCE TO MAFLD’’.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients of either sex male or female
- •Age group equal and more then18 years and equal and less then 60 years
- •USG finding suggestive of fatty liver grade 1 and
- •4.Clinical sign and symptoms suggesting of Yakrita Roga that Aruchi ,Daurablya, Avipak,Aadhman, Vibandh.
- •5.Willingness to participate in the study and provide informed consent.
排除标准
- •Pregnant and lactating women.
- •2.Patients with history of autoimmune hepatitis, drug abuse, Acute and chronic hepatitis.
- •Patients with complications of metabolic syndrome such as cerebrovascular accident, myocardial infarction, chronic kidney diseases, suffering from cirrhosis, ascites, variceal haemorrhage, coagulopathy, hepatorenal syndrome.
- •Patient having blood pressure 160/90 mm of Hg and more according JNC-8 .
- •5.Patient of DM type 1 (IDDM).
- •6.Patients not willing to fill consent forms.
研究者
Bhuvnesh Kumar Gothwal
National institute of Ayurveda, Jaipur